Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says

Executive Summary

Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says

You may also be interested in...



Generic Zocor Prompts Some Part D Plans To Make Formulary Adjustments

The largest Medicare Part D sponsors are taking a variety of approaches to Zocor's formulary position following the introduction of a generic version of simvastatin, but they are not going to some of the extremes that non-Medicare commercial plans are

Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned

The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward

After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight

Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13

Latest News
See All
UsernamePublicRestriction

Register

PS047703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel